How can trispecifics be integrated with CELMoDs in myeloma treatment?
The panel discussed combining trispecifics with mezigdomide, noting the strong activity and improved tolerability of targeting BCMA and CD38. They also discussed how
Focus on CELMoDs
EHA 2026
Meetings / Conferences
Multiple Myeloma
Roundtable Discussions
Video Interviews
EHA 2026
Myelodysplastic Syndromes
News
Video Interviews
Dr. Rami Komrokji on the latest in MDS updates
From EHA 2026, Dr. Komrokji shares the latest research in MDS, and his thoughts on what is next in the field.
Myelodysplastic Syndromes
News
Young Investigator Program
Meet SOHO 2026 YIP recipient: Maria Felix Torres, MD
During her residency in the United States, Dr. Torres became even more intrigued by the field. “I was able to see the impact
Multiple Myeloma
News
FDA accepts NDA for mezigdomide combo in relapsed or refractory myeloma
The US Food and Drug Administration has accepted a new drug application for mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) in patients
News
Society Updates
SOHO announces launch of 2nd podcast focused on education titled, ‘SOHO Spotlight’
The society is excited to announce the first episode of its educational podcast, SOHO Spotlight.
Focus on CELMoDs
Past Roundtable Discussions
Multiple Myeloma
Roundtable Discussions
Video Interviews
What are the distinguishing features of CELMoDs?
In this roundtable discussion on myeloma and CELMoDs, the panel discuss mechanism of action, overcoming drug resistance, and other distinguishing features of this
EHA 2026
Meetings / Conferences
Myeloproliferative Neoplasms
Primary Myelofibrosis
Video Interviews
Early-phase trial data of INCA033989 shows durable responses in MF
Claire Harrison, MD, deputy chief medical officer at the Guy's and St. Thomas' NHS Foundation in the United Kingdom, discusses results from the
Ambassador Program
Leukemia
Acute Lymphoblastic Leukemia
News
Society Updates
Anthony Goldstone built a transplant program. It started in a broom cupboard.
At age 28, he was a senior registrar in clinical and laboratory haematology at Addenbrooke’s Hospital in Cambridge. After earning his MRCPath at
ASCO 2026
News
Pemivibart safe, effective for prevention of COVID-19 in immunocompromised cancer patients
The study assessed the safety and outcomes of pemivibart in the oncology subset from the open-label, single-arm, immunocompromised Cohort A of the phase
Leukemia
News
FDA approves pivekimab sunirine-pvzy for BPDCN
The drug had earlier received the FDA’s breakthrough designation and orphan drug designation, making the application eligible for priority review. Efficacy was evaluated